Ex vivo stimulation of renal tubular p-aminohippurate transport by dexamethasone and triiodothyronine in human renal cell carcinoma

被引:6
作者
Fleck, C [1 ]
Bachner, B
Göckeritz, S
Karge, E
Strohm, U
Schubert, J
机构
[1] Univ Jena, Inst Pharmacol & Toxicol, D-07740 Jena, Germany
[2] Univ Jena, Dept Urol, D-6900 Jena, Germany
来源
UROLOGICAL RESEARCH | 2000年 / 28卷 / 06期
关键词
renal tubular transport; p-aminohippurate; stimulation; renal cell carcinoma; dexamethasone; triiodothyronine;
D O I
10.1007/s002400000142
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
This paper is the third of a long-term planned series of papers dealing with ex vivo investigations of drug transport in human kidney. The aims of this study are (a) to investigate whether or not human renal cell carcinoma (RCC) can actively accumulate p-aminohippurate (PAH) and (b) to test the response of RCC on dexamethasone or triiodothyronine (T3) using tissue slices ex vivo. By this approach, the accumulation capacity of RCC should be stimulated as a prerequisite for an increased uptake of anti-tumour drugs. Tissue slices of RCC samples of 30 patients were incubated for 24 h in Williams medium E containing 0.01-50 muM dexamethasone or T3. Thereafter, slices were placed in PAH-containing Cross-Taggart medium, and PAH uptake into kidney tissue was measured for 2 h under standardised conditions as described previously. In intact human renal cortical slices, PAH uptake capacity, expressed as slice to medium ratio (Q(S/M)), was about 2.8 +/- 0.16 after 24 h of incubation and increased significantly in dexamethasone-containing medium in a concentration-dependent manner, up to similar to 150%, whereas T3 did not influence PAH accumulation. On the other hand, in RCC the PAH accumulation capacity was completely abolished (Q(S/M)similar to1). However, after administration of dexamethasone, the accumulated amount of PAH increased significantly in RCC tissue in a concentration-dependent manner, up to similar to 190%. T3 was without effect in RCC, too. Surprisingly, the dexamethasone-mediated stimulation could be differentiated into responders and non-responders, with maximal effects at different concentrations for each patient. Nevertheless, the maximal transport rates remained low in RCC, even under hormone influence. In conclusion, a moderate stimulation of tubular transport capacity can be shown ex vivo in human RCC. This phenomenon is only of a relatively low degree compared with intact renal tissue. However, in principle, the response of RCC on dexamethasone could form a basis for further therapeutic strategies to overcome multi-drug resistance in RCC patients. For this purpose, additional experiments analysing the expression of transporters of the ABC cassette-type are in progress.
引用
收藏
页码:383 / 390
页数:8
相关论文
共 36 条
[1]   A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma [J].
Amato, R ;
Meyers, C ;
Ellerhorst, J ;
Finn, L ;
Kilbourn, R ;
Sella, A ;
Logothetis, C .
ANNALS OF ONCOLOGY, 1995, 6 (09) :911-914
[2]  
AZPODIEN J, 1998, NIERENZELLKARZINOM R, P160
[3]  
Bratton AC, 1939, J BIOL CHEM, V128, P537
[4]  
BRAUNLICH H, 1987, PHARMAZIE, V42, P846
[5]  
EFFERTH T, 1995, ONKOLOGIE, V18, P258
[6]  
FLECK C, 1981, ARCH INT PHARMACOD T, V252, P133
[7]   Tubular PAH transport capacity in human kidney tissue and in renal cell carcinoma: Correlation with various clinical and morphological parameters of the tumor [J].
Fleck, C ;
Gockeritz, S ;
Schubert, J .
UROLOGICAL RESEARCH, 1997, 25 (03) :167-171
[8]   In vitro stimulation of renal tubular p-aminohippurate transport by dexamethasone in rat kidneys and in intact kidney tissue of patients suffering from renal cell carcinoma [J].
Fleck, C ;
Kratochwil, E ;
Winterstein, K ;
Gockeritz, S ;
Schubert, J .
UROLOGICAL RESEARCH, 1998, 26 (02) :143-148
[9]   RENAL HANDLING OF DRUGS AND AMINO-ACIDS AFTER IMPAIRMENT OF KIDNEY OR LIVER-FUNCTION - INFLUENCES OF MATURITY AND PROTECTIVE TREATMENT [J].
FLECK, C ;
BRAUNLICH, H .
PHARMACOLOGY & THERAPEUTICS, 1995, 67 (01) :53-77
[10]  
Fleck C, 1997, EXP TOXICOL PATHOL, V49, P81